查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1966143

脊髓性肌肉萎縮症 (SMA) 治療全球市場規模、佔有率、趨勢和成長分析報告：2026-2034 年

Global Spinal Muscular Atrophy (SMA) Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 136 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計脊髓性肌肉萎縮症 (SMA) 治療市場規模將從 2025 年的 58.6 億美元成長到 2034 年的 271.8 億美元，2026 年至 2034 年的複合年成長率為 18.58%。

由於基因療法的進步和早期診斷水平的提高，脊髓性肌肉萎縮症 (SMA) 的治療市場正在快速成長。 SMA 曾被認為是一種致命的兒童疾病，治療選擇有限，但如今，緩解疾病藥物和基因替代療法的出現使患者受益匪淺。新生兒篩檢的普及和早期療育顯著改善了患者的預後，從而推動了市場成長。

關鍵成長要素包括反義寡核苷酸療法的進步、基因療法的創新以及針對罕見疾病的強力的監管激勵措施。生技公司與醫療服務提供者之間的策略合作擴大了分銷網路，並改善了患者的就醫途徑。臨床醫生和患者權益組織的高度重視進一步促進了早期診斷和及時有效的治療。

展望未來，隨著新一代基因編輯技術和更完善的遞送系統的出現，市場有望不斷發展。長期療效數據和適應症的擴大可望惠及更多患者。然而，高昂的治療費用和保險覆蓋方面的挑戰仍然是需要重點考慮的因素。持續的技術創新和支持性的醫療政策將塑造未來的成長軌跡。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球脊髓性肌肉萎縮症 (SMA) 治療市場：按類型分類

  • 市場分析、洞察與預測
  • 1型
  • 類型 2
  • 3型
  • 4型

第5章 全球脊髓性肌肉萎縮症 (SMA) 治療市場：依治療方式分類

  • 市場分析、洞察與預測
  • 基因治療
  • 藥物

第6章 全球脊髓性肌肉萎縮症（SMA）治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 注射

第7章 全球脊髓性肌肉萎縮症（SMA）治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Biogen
    • Novartis AG
    • Pfizer Inc
    • Ionis Pharmaceuticals
    • BiohavenLtd
    • F. Hoffmann-La Roche Ltd
    • Cytokinetics
    • Scholar RockInc
    • PTC Therapeutics
    • NMD PHARMA A/S
簡介目錄
Product Code: VMR11210467

The Spinal Muscular Atrophy (SMA) Treatment Market size is expected to reach USD 27.18 Billion in 2034 from USD 5.86 Billion (2025) growing at a CAGR of 18.58% during 2026-2034.

The spinal muscular atrophy (SMA) treatment market has grown rapidly due to breakthroughs in genetic therapies and early diagnosis initiatives. Previously considered a fatal pediatric disorder with limited options, SMA now benefits from disease-modifying drugs and gene replacement therapies. Increased newborn screening and earlier intervention have significantly improved patient outcomes, driving market expansion.

Key drivers include advancements in antisense oligonucleotide therapies, gene therapy innovations, and strong regulatory incentives for rare diseases. Strategic collaborations between biotech firms and healthcare providers have enhanced distribution and patient access. High awareness among clinicians and patient advocacy groups has further supported early diagnosis and timely treatment initiation.

Looking ahead, the market is expected to evolve with next-generation gene-editing approaches and improved delivery systems. Long-term efficacy data and expanded indications may broaden patient eligibility. Nevertheless, high therapy costs and reimbursement challenges remain significant considerations. Continued innovation and supportive healthcare policies will shape future growth trajectories.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Type 1
  • Type 2
  • Type 3
  • Type 4

By Treatment

  • Gene Therapy
  • Drug

By Route of Administration

  • Oral
  • Injection

COMPANIES PROFILED

  • Biogen, Novartis AG, Pfizer Inc, Ionis Pharmaceuticals, Biohaven, Ltd, F HoffmannLa Roche Ltd, Cytokinetics, Scholar Rock, Inc, PTC Therapeutics, NMD PHARMA AS

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Type 1 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Type 2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Type 3 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Type 4 Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Treatment
  • 5.2. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Drug Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Type
    • 7.2.2 By Treatment
    • 7.2.3 By Route Of Administration
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Type
    • 7.3.2 By Treatment
    • 7.3.3 By Route Of Administration
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Type
    • 7.4.2 By Treatment
    • 7.4.3 By Route Of Administration
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Type
    • 7.5.2 By Treatment
    • 7.5.3 By Route Of Administration
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Type
    • 7.6.2 By Treatment
    • 7.6.3 By Route Of Administration
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SPINAL MUSCULAR ATROPHY (SMA) TREATMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Biogen
    • 9.2.2 Novartis AG
    • 9.2.3 Pfizer Inc
    • 9.2.4 Ionis Pharmaceuticals
    • 9.2.5 BiohavenLtd
    • 9.2.6 F. Hoffmann-La Roche Ltd
    • 9.2.7 Cytokinetics
    • 9.2.8 Scholar RockInc
    • 9.2.9 PTC Therapeutics
    • 9.2.10 NMD PHARMA A/S